Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, July 1, 2022
[ 12:00 AM ] - United States, WOPRAI
Thu, June 30, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Serge Belanger Maintained (TRVI) at Strong Buy with Increased Target to $10 on, Jun 30th, 2022
Serge Belanger of Needham, Maintained "Trevi Therapeutics, Inc." (TRVI) at Strong Buy with Increased Target from $8 to $10 on, Jun 30th, 2022.
Serge has made no other calls on TRVI in the last 4 months.
There are 2 other peers that have a rating on TRVI. Out of the 2 peers that are also analyzing TRVI, 0 agree with Serge's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Serge
- Leland Gershell of "Oppenheimer" Initiated at Buy and Held Target at $10 on, Wednesday, May 25th, 2022
- Nathan Weinstein of "Aegis Capital" Initiated at Strong Buy and Held Target at $10 on, Tuesday, March 29th, 2022
